A single-centre analysis in Germany has found that polypharmacy is common among MS patients, with 56.5% of patients reporting use of 5 or more medications (Frahm et al. Sci Rep 2019;9:3743; free full text at www.ncbi.nlm.nih.gov/pmc/articles/PMC6403326/pdf/41598_2019_Article_40283.pdf). Most patients were currently taking a disease-modifying therapy (DMT) for MS. Other medications commonly used were gastrointestinal drugs, thrombosis prophylaxis drugs, osteoporosis drugs, antihypertensives and sedatives.
The study population (n=306) comprised patients with CIS/RRMS (62.7%), SPMS (26.1%) and PPMS (11.1%). Average age was 48.7 years. A total of 72.5% were in a relationship and 37.6% were employed. Median duration of MS was 11 years (range 6 weeks to 50 years).